Ubiquitin ligases as therapeutic targets in HIV-1 infection

Expert Opin Ther Targets. 2008 Feb;12(2):131-43. doi: 10.1517/14728222.12.2.131.

Abstract

Background: Introduction of highly active antiretroviral therapy has led to a profound reduction in human immunodeficiency virus (HIV) related mortality; although, the complete eradication of the virus from infected individuals has never been achieved. In addition, due to the high mutation and evolution rate, drug-resistant viruses are continuously emerging.

Objective: Genetically more stable cellular pathways represent attractive targets for innovative antiviral strategies, especially the ubiquitin proteasome system, which regulates various steps in the HIV replication cycle.

Methods: This review focuses on certain interactions of HIV and E3 ligases as a major player in the ubiquitin proteasome system.

Results/conclusion: Due to the importance in HIV replication, and together with the high substrate specificity, E3 ligases can be considered as bona fide targets to interfere with HIV infection.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Anti-HIV Agents / pharmacology*
  • Anti-HIV Agents / therapeutic use
  • HIV Infections / drug therapy*
  • Humans
  • Ubiquitin-Protein Ligases / antagonists & inhibitors*
  • Ubiquitin-Protein Ligases / metabolism

Substances

  • Anti-HIV Agents
  • Ubiquitin-Protein Ligases